Table 1.

Durvalumab treatment exposure

	Durvalumab plus EP (n = 265)	Durvalumab plus tremelimumab plus EP (n = 266)
Median number of durvalumab doses (range)	7.0 (1-52)	6.0 (1-46)
Total duration of durvalumab exposure, n (%)
≥1 year	54 (20.4)	49 (18.4)
≥2 years	32 (12.1)	30 (11.3)
≥3 years	24 (9.1)	21 (7.9)
Median total duration of durvalumab, weeks (range)	28.0 (0.3-198.7)	23.1 (0.1-190.0)
Durvalumab dose delays, n (%)	152 (57.4)	157 (59.0)
Durvalumab dose interruptions, n (%)	4 (1.5)	4 (1.5)

EP, etoposide plus either cisplatin or carboplatin.